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Abstract 
Opioid use and resultant deaths have been declared an epidemic.  The purpose of this project was 
to develop an outpatient primary care evidence-based toolkit for medication-assisted treatment 
(MAT) in opioid dependence for Alaska nurse practitioners (NPs).  The focus was to enhance 
provider knowledge of MAT modalities and to facilitate practice implementation with an overall 
goal of increasing knowledgeable health professionals thereby increasing patient access to 
treatment.  The Plan, Do, Study, Act framework was used to implement an educational 
presentation of current MAT modalities and to develop the MAT toolkit as previously 
mentioned.  A post-implementation survey was used to evaluate the project outcomes.  The data 
obtained from the questionnaire demonstrated participant knowledge of MAT modalities with 
the intent to provide MAT and to use the toolkit in future clinical practice. 
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Development of Evidence-Based Tools for Delivery of Medication-Assisted Treatment in 
Opioid Dependency 
Opioid dependency has been a growing health concern globally and nationwide.  World 
Health Organization (WHO, 2014) reported an estimated 15 million people worldwide were 
addicted to opioids, including both heroin and prescription opioids.  Of that 15 million, the 
United States (US) accounts for just over two million opioid addicts.  Drug overdose in the US is 
now the leading cause of accidental death (American Society of Addiction Medicine [ASAM], 
2016).  In 2012, the overdose deaths related to opioid pain relievers in Alaska were more than 
double the national rate ("SOA Epidemiology," 2016).  
In 2015, opioid pain relievers and heroin accounted for more than 80% of the total drug 
overdose deaths in the state of Alaska.  From less than five deaths in 2010 to 34 in 2015, this ten-
fold increase of opioid overdose deaths illustrates the significance of the opioid epidemic present 
in our state ("State of Alaska Epidemiology," 2016).  While there have been effective treatments 
for opioid dependence, only 10% of people who needed treatment were receiving care (WHO, 
2014).  In 2012, 14,000 of the 19,000 illicit drug users in Alaska felt they needed substance 
abuse treatment; however, a single day count for individuals enrolled in a substance abuse 
treatment program in Alaska for 2012 was 3,658.  Of these enrollees, only 168 were in an opioid 
treatment program (SAMHSA, 2015b).  
Problem and Topic Overview 
One particular measure in addressing the opioid epidemic was to increase the availability 
of opioid dependence treatment (Volkow, Frieden, Hyde, & Cha, 2014; WHO, 2014).  
Guidelines for treatment have been a combination of psychosocial interventions and MAT 
(Kampman & Jarvis, 2015).  The three Federal Drug Administration (FDA) approved MAT 
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options include methadone, buprenorphine, and naltrexone (ASAM, 2015; SAMHSA, 2016a).  
Opioid use and resultant deaths have been declared an epidemic with suboptimal treatment as a 
likely contributor; inadequate access to treatment due to the limited amount of providers who 
were willing or able to provide these treatments is a form of suboptimal treatment (Kampman & 
Jarvis, 2015).  
A variety of care settings can be used to deliver opioid dependence treatment, such as 
residential or hospital opioid treatment facilities (OTP), and office-based or outpatient opioid 
treatment programs (OBOT).  Though three MAT options are available, the utilization of these 
medications for opioid dependency has not been widely available.  In 2012, of the 2.5 million 
opioid dependent Americans age 12 or older, less than 1 million received MAT (SAMHSA, 
2013). 
Nearly half of the patients seen by primary care providers report some issue related to 
substance use or abuse, indicating that initiation of treatment often begins in the primary care 
setting (SAMHSA, 2015a).  When opioids travel through the bloodstream, they attach to mu 
opioid receptors in the brain and activate the reward system, which gives off a feeling of 
pleasure.  When opioids activate the reward system in the absence of significant pain, they can 
motivate repeated use of opioids to maintain that sense of pleasure and lead to opioid misuse or 
abuse, tolerance, and dependence (Kosten & George, 2002).  Repeated exposure to escalating 
opioid dosages can produce abnormal brain functioning when the drugs are both present and 
when they are not.  The results of these brain alterations are opioid tolerance (the need to take 
increasingly higher doses of opioids to achieve the same opioid effects) and opioid dependence 
(the susceptibility to withdrawal symptoms in the absence of opioids after tolerance has 
occurred) (Kosten & George, 2002).  Like other chronic diseases such as diabetes, asthma, and 
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hypertension, the management of opioid dependence should be approached with evidence-based 
treatments immediately available to prevent the loss of opportunity to treat (ASAM, 2015; 
National Institute on Drug Abuse [NIDA], 2014).  With a vast majority of Nurse Practitioners 
(NP) holding family practice certifications, there is an opportunity for family NPs to decrease the 
gap in treatment availability by providing outpatient MAT (American Association of Nurse 
Practitioners [AANP], 2016). 
Significance  
The opioid drug class includes the street drug heroin, in addition to, prescription 
medications such as oxycodone, hydrocodone, codeine, morphine, and fentanyl.  Routine use of 
opioids can lead to dependence or abuse and can result in overdose and death (NIDA, 2014).  In 
2012, approximately 335,000 persons ages 12 years or older in the US reported current heroin 
use and 4.9 million reported the current use of nonmedical pain relievers (SAMHSA, 2013).  In 
that same period, 23,000 Alaskans ages 18 years or older reported use of nonmedical pain 
relievers in the past year and 19,000 people ages 18 years or older who reported current use of 
illicit drugs other than marijuana (SAMHSA, 2016b).  The significant amount of opioid 
dependent individuals presents both health and financial concerns for Alaska and the nation. 
Societal Impact 
In 2007, the total economic burden of prescription opioid dependency equaled $55.7 
billion dollars; three categories included in this cost were workplace, healthcare, and criminal 
justice costs (Birnbaum, White, Schiller, Waldman, Cleveland, & Roland, 2011).  Lost 
workplace productivity accounted for $25.6 billion of the deficit, health care costs was $25.0 
billion, and the remaining $5.1 billion came from criminal justice costs (Birnbaum et al., 2011).  
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This tremendous economic burden has been a result of the multidimensional consequences due 
to the complexity of the disorder. 
Opioid dependence can involve every aspect of an individual’s functioning; personality 
and behavior changes of opioid abuse can have negative consequences which can manifest 
symptoms in marriage or relationships, home and family life, education, employment, health, 
personality, finances, and law and order (NIDA, 2012).  These negative consequences reach 
beyond the affected individual.  Hardship within families can arise due to misunderstandings of 
the disease process or the person’s behavior due to drug use, draining of family resources, illness 
or death as a result of substance abuse, distortion of interpersonal family relationships, and 
violence (NIDA, 2009).  
Health care consequences of opioid use disorder may include but are not limited to 
hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV), psychiatric illnesses, 
and overdose or death (NIDA, 2014).  In 2010, the total hospital costs for drug abuse-related 
illness in Alaska was $12.9 million (Alaska Advisory Board on Alcoholism and Drug Abuse, 
McDowell Group, Inc. [AABADA], 2012).  These health consequences have a negative impact 
on the individual, the health care system, and families that provide financial and emotional 
support.  
Chronic opioid abuse has been shown to cause long-lasting changes in the brain that has 
contributed to the individual’s compulsion to seek and use drugs despite the catastrophic 
consequences (NIDA, 2014).  Incarcerations and entering the criminal justice system have been 
included within these consequences.  The link continues between substance abuse and 
criminality as individuals often turn to crime as a means to supporting their addiction.  In 2010, 
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there were 18,296 arrests in Alaska that were related to substance abuse with 1,529 resulting in 
incarcerations at the cost of $56.7 million (AABADA, 2012). 
Though effective treatments for opioid dependence exist, only 10% of people who have 
needed treatment were receiving it (WHO, 2014).  In Alaska, 14,000 of the 19,000, illicit drug 
users reported needing treatment but were not receiving it; this equated to only 27% of the 
opioid-dependent individuals receiving the medical care required for their chemical dependence 
(SAMHSA, 2016b).  Further investigation of treatment rates showed a single day count for 
people enrolled in substance abuse treatment in Alaska was 3,658 during 2012; of these 
enrollees, only 168 were in an opioid treatment program (SAMHSA, 2015b).  This shows a vast 
disparity in the number of individuals needing treatment and those who are receiving it.  
 Increasing access and availability of MAT are essential components of a comprehensive 
response to the opioid epidemic and could decrease the significant and widespread impacts of 
this disease (NIDA, 2012; Volkow et al., 2014).  Family practice NPs in Alaska can increase 
access to treatment by providing MAT in the outpatient setting, as they are well-trained 
providers in health promotion and disease prevention.  The scope of practice of NPs includes the 
assessment, diagnosis, treatment, and management of illness (AANP, 2015).  Opioid abuse is a 
chronic disease that NPs can diagnose and treat by preventing relapse and adverse effects, which 
include death, long-term health consequences, adverse effects on relationships, employment 
issues or job loss, legal problems or incarceration, and psychological problems (ASAM, 2013; 
Birnbaum et al., 2011).  The underutilization of MAT in the primary care setting has created an 
opportunity for NPs to decrease the gap in treatment access and availability.   
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Practice Improvement Question 
 Clinical inquiry questions are often designed using the PICOT format.  Utilizing the 
PICOT method facilitates the development of a concise question to address proposed solutions of 
an observed problem.  The PICOT question includes a patient population of interest (P), 
intervention or area of interest (I), comparison intervention or group (C), outcome (O), and time 
(T) (Melnyk, Fineout-Overholt, Stillwell, & Williamson, 2010).   
(P)  The population encompasses licensed family nurse practitioners (NP) within Alaska working 
in outpatient primary care. 
(I)  The interventions include education of MAT modalities within the scope of practice for 
Alaska NPs and implementation of an evidence-based toolkit providing guidelines/protocols and 
information necessary for the implementation of MAT into clinical practice. 
(C)  There is no comparison.  
(O)  Increase provider understanding of MAT options, satisfaction with training, and utility or 
intent to use the MAT toolkit. 
(T)  The timeline is as follows: education and evidence-based toolkit implementation in a 
primary care setting with post-implementation survey data collection on the same day. 
Research Question   
 Does education of MAT modalities and the implementation of an evidence-based toolkit 
increase understanding of MAT options and facilitate the utilization of MAT by Alaska family 
nurse practitioners working in primary care? 
Purpose 
The purpose of this practice improvement project was to develop an outpatient primary 
care evidence-based toolkit for MAT in opioid dependence for Alaska nurse practitioners.  The 
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project aimed to enhance provider knowledge of MAT modalities and to facilitate practice 
implementation with an overall goal of increasing the availability of trained and knowledgeable 
health professionals thereby increasing patient access to treatment for opioid dependency.  
Literature Review  
Current practice recommendations indicate opioid dependence is a chronic illness to be 
treated with a combination of psychosocial and pharmacotherapy (ASAM, 2015; National 
Guideline Clearinghouse [NGC], 2011).  Three pharmacological treatments approved by the 
federal drug administration (FDA) for opioid dependency are methadone, buprenorphine, and 
naltrexone (ASAM, 2015; SAMHSA, 2016a).  The choice of medication used for treatment is 
multifactorial; providers must consider key features of all modalities.   
Medication-Assisted Treatment Options 
Methadone.  This drug is a long-acting synthetic opioid agonist, which activate opioid 
receptors (SAMHSA, 2016a; U.S. Department of Justice Drug Enforcement Administration 
[U.S. DOJ DEA], 2006).  It is used to suppress opioid withdrawal, block the effects of illicit 
opioids, reduce opioid cravings, and reduce or stop the use of illicit opioid.  It is taken orally and 
can be used as a long-term maintenance medication to prevent relapse  (ASAM, 2015; NGC, 
2011; NIDA, 2012; SAMHSA, 2016a).  Methadone is also associated with physiologic 
dependence and has a risk of diversion, abuse, and overdose if drug dosing is not carefully 
monitored; it may only be prescribed by a physician and dispensed within a SAMHSA-certified 
Opioid Treatment Program (OTP) (ASAM, 2015; NIDA, 2012; SAMHSA, 2016a).  
Buprenorphine.  This drug is a synthetic partial opioid agonist, which also activates 
opioid receptors, but has a smaller response (SAMHSA, 2016a; U.S. DOJ DEA, 2006).  It is also 
used to suppress opioid withdrawal, block the effects of illicit opioids, reduce opioid cravings, 
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and reduce or stop the use of opioids (ASAM, 2015; NGC, 2011; NIDA, 2012; SAMHSA, 
2016a).  Like methadone, buprenorphine is taken orally and can be used as a long-term 
maintenance medication to prevent relapse; it also carries a risk of physiological dependence, 
though less severe than that of methadone (ASAM, 2015; NIDA, 2012; SAMHSA, 2016a).  
Buprenorphine can only be prescribed by providers, including NPs, with board certification in 
addiction medicine or addiction psychiatry or have completed specialized training to qualify for 
the federal waiver required for prescriptive authority (NIDA, 2014; U.S. DOJ DEA, 2006). 
Naltrexone.  This drug is a synthetic opioid antagonist that blocks opioids from binding 
to receptor sites to prevent the euphoria and reward response effect caused by opioids (ASAM, 
2015; NIDA, 2012; SAMHSA, 2016a).  It is supplied as both an oral (taken daily) and injectable 
(taken monthly) medication and is used to block the effects of illicit opioids and reduce opioid 
cravings, and reduce or stop the use of opioids (ASAM, 2015; NIDA, 2012; SAMHSA, 2016a).  
Unlike methadone and buprenorphine, naltrexone is not indicated for opioid withdrawal, does 
not carry the potential for abuse or diversion, and does not require special certification or waivers 
for prescription (ASAM, 2015; NIDA, 2012; SAMHSA, 2016a; U.S. DOJ DEA, 2006).  The 
injectable form of naltrexone is referred to as XR-NTX.   
Guidelines for Treatment 
 To assist in the evaluation and treatment of opioid use disorders, the ASAM released The 
National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving 
Opioid Use (2015).  The guideline is composed of scientific evidence and clinical knowledge 
from 34 previous guidelines that address the use of medications and psychosocial treatments for 
opioid use disorders.  The existing 34 guidelines were based on systematic reviews of the 
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literature and offer the highest level of evidence-based recommendations included in the new 
ASAM guideline (ASAM, 2015).  
Current practice guidelines have recommended treatment of opioid use disorders to 
include a combination of withdrawal management and psychosocial therapy or psychosocial 
therapy combined with methadone, buprenorphine, or naltrexone (ASAM, 2015).  Aside from 
methadone and buprenorphine, the alpha2-adrenergic agonist clonidine has also shown to be an 
effective treatment for opioid withdrawal management (Gowing, Farrell, Ali, & White, 2016).  
While a recent systematic review of the literature found that clonidine was more effective than 
placebo in the management of opioid withdrawal, it is not approved by the FDA for this 
indication (Gowing et al., 2016; ASAM, 2015).  As such, withdrawal management will not be 
discussed in depth, as NP general prescriptive authority for MAT is limited to naltrexone.  
Caution should be taken to prevent severe withdrawal symptoms caused by naltrexone; use only 
after detoxification and when the individual is no longer physically dependent on opioids 
(ASAM, 2015; NIDA, 2012; SAMHSA, 2016a). 
Opioid Withdrawal Treatment Assessment 
 The first step to providing MAT is the assessment and diagnosis of opioid use disorder to 
determine the need for treatment (ASAM, 2015; SAMHSA, 2016a).  This step includes 
measuring the severity of substance use disorder and withdrawal, identifying co-occurring 
diseases or conditions, evaluating the effect of the opioid use on physical and psychological 
function, determining outcomes of previous treatment, and obtaining the patients’ medical and 
behavioral health history (ASAM, 2015; SAMHSA, 2016a).  If the patient is experiencing 
moderate to severe withdrawal, inpatient treatment referral may be necessary for medically 
managed withdrawal from opioids (ASAM, 2015; NIDA, 2012; SAMHSA, 2016a). 
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After establishing the diagnosis of substance use disorder, the choice of medication 
treatment should be a shared decision between the patient and provider (ASAM, 2015; 
SAMHSA, 2016a).  Patient education about the risks and benefits of all medication options are 
reviewed, including relapse and overdose prevention.  Referral to a higher level of care can also 
be made at this time if treatment with XR-NTX is not appropriate (ASAM, 2015; NIDA, 2012; 
SAMHSA, 2016a). 
Medication-Assisted Treatment 
While the use of methadone and buprenorphine has long been established in the treatment 
of opioid abuse, prescribing these medications may be somewhat limited due to federal 
regulations (ASAM, 2015; NGC, 2011).  As previously stated, methadone may only be 
prescribed or dispensed by a SAMHSA-certified OTP and buprenorphine by providers who meet 
requirements for its prescriptive authority (NIDA, 2014; SAMHSA, 2015a; U.S. DOJ DEA, 
2006).  Practitioner limitations of these medications contribute to the limited access and 
availability of MAT both nationwide and within the state of Alaska. 
For individuals living in areas where methadone and buprenorphine are unavailable, for 
those who are highly motivated and want to taper off their current agonist therapy, or persons not 
wanting treatment with an opioid agonist use of XR-NTX should be considered (ASAM, 2015; 
NIDA, 2012; SAMHSA, 2016a).  If the patient is medically and psychologically stable and XR-
NTX deemed appropriate, the provider and patient then develops a comprehensive, 
individualized treatment plan; this includes integration of counseling and other psychosocial 
therapies, social support and mutual help programs with pharmacological treatment (ASAM, 
2015; NIDA, 2012; SAMHSA, 2016a).  In compliance with the state of Alaska nursing statutes, 
Drug Enforcement Agency (DEA) policies, and national practice guidelines, the only MAT 
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option available to NPs that does not require special licensing, certification, or waivers is XR-
NTX (State of Alaska Board of Nursing [SOA BON], 2014; U.S. DOJ DEA, 2006).  While no 
single treatment is appropriate for everyone, XR-NTX can be useful when methadone and 
buprenorphine are unavailable or inaccessible (ASAM, 2015; NIDA, 2012; SAMHSA, 2015a, 
SAMHSA, 2016a).  The FDA approved the injectable release naltrexone (XR-NTX) for the 
treatment of alcohol dependence in 2006 and 2010 for the treatment of opioid dependency 
(Alanis-Hirsch et al., 2015).  In comparison to receiving no MAT for opioid dependence, XR-
NTX has been indicated to be safe and efficacious.  
In 2011, a double-blind placebo-controlled randomized trial was conducted to assess the 
efficacy, safety, and patient-reported outcomes of once-monthly dose XR-NTX in the treatment 
of opioid dependency (Krupitsky, Nunes, Ling, Illeperuma, Gastfriend, & Silverman, 2011).  
The 24-week trial included opioid dependent individuals ages 18 years and older across 13 
treatment sites in Russia; after randomization to XR-NTX (n = 126) or placebo (n = 124) groups, 
analyses of the primary endpoint of abstinence of opioids during weeks 5-24 was 90.0% (95% CI 
= 69.9, 92.4) in the XR-NTX group and 35.0% (11.4, 63.8) in the placebo group (PBO) (p < .01).  
Analyses of secondary endpoints were self-reported opioid-free days, opioid craving scores, the 
number of days in retention, and relapse to physiological opioid dependence; all endpoints 
resulted in statistically significant differences (p < .01) indicating the superiority of XR-NTX 
treatment over placebo (Krupitsky et al., 2011).  
The result of this study was pivotal in the approval of XR-NTX for opioid dependence in 
the US as it provided significant information in the use and efficacy of XR-NTX as an alternative 
pharmacotherapy in the treatment of opioid dependence (Syed & Keating, 2013).  The study 
demonstrated that opioid-dependent adults voluntarily seeking treatment who received XR-NTX 
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when compared to those who received placebo had a higher treatment retention rate, more 
opioid-free weeks, fewer relapses to physiological opioid dependence, and greater reductions in 
opioid cravings (Krupitsky et al., 2011).  
Following the six-month trial, there was a 52-week open-label extension phase that 
continued to measure the long-term safety and effectiveness of XR-NTX (Krupitsky, Nunes, 
Ling, Gastfriend, Memisoglu, & Silverman, 2013). During the extension phase (n = 114), 67 
XR-NTX patients continued with monthly injections, and 47 patients transitioned from PBO to 
receive XR-NTX. 62.3% (95% CI = 52.7, 71.2) of the participants completed the trial; primary 
reasons for discontinuation was the withdrawal of consent (18.4%) and loss to follow-up (11.4%) 
(Krupitsky et al., 2013).  Overall, 50.9% (95% CI = 41.5, 60.4) were abstinent from opioids, 
21.1% of patients reported adverse events, 6.1% experienced injection site reactions, and 16.7% 
had elevations in liver function (Krupitsky et al., 2013).  Participants with elevated liver enzymes 
were equally from the original group of XR-NTX participants, and PBO to XR-NTX and serum 
elevations were clinically judged as non-significant (Krupitsky et al., 2013).  The study identified 
no new safety concerns were identified, and long-term treatment with XR-NTX showed 
encouraging rates of retention and opioid abstinence, low rate of adverse events, no severe 
adverse events, and a low overall rate of injection site pain (Krupitsky et al., 2013).  
Comparison of MAT options to determine the superiority of one drug over the other is 
difficult due to the lack of evidence-based literature.  Systematic long-term studies of MAT have 
been rare, and comparison of treatment retention rates has been difficult due to the varying study 
designs and characteristics (Krupitsky, 2013; Syed & Keating, 2013).  To date, there have been 
no published clinical trials directly comparing the efficacy and safety of XR-NTX with 
methadone or buprenorphine in the treatment of opioid dependency (Syed & Keating, 2013).  
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Outpatient Treatment 
Access to MAT with methadone and buprenorphine treatment has been limited in part 
due to the small number of qualified prescribing providers.  It has been currently estimated that 
only two OTP facilities and 19 buprenorphine-certified physicians have been available in the 
state (Opiate Addiction and Treatment Resource, n.d.).  The issue of a limited number of 
buprenorphine-certified providers was further compounded by the fact that each prescriber may 
only treat a maximum of 30 to 100 patients at any given time (U.S. DOJ DEA, 2006).  Increasing 
the number of outpatient primary care providers who were knowledgeable and able to provide 
outpatient MAT could increase treatment availability (Volkow et al., 2014).   
Recently, a web-based survey study was conducted to estimate the demand for primary 
care-based treatment for substance and alcohol use disorders.  The 344 study participants with 
substance use disorder were randomly assigned to one of three treatment conditions (usual care, 
primary care, or collaborative care) to determine their willingness to enter treatment based on the 
characteristics of the treatment alone (Barry, Epstein, Fielin, Fraenkel, & Busch, 2016).  The 
description of usual care included treatment in a specialty drug treatment center with ongoing 
counseling, medication, or both.  Primary care included the same treatment as usual care, but in 
an office setting with the added benefits of receiving care for other medical issues and the option 
of a referral to addiction specialty for more intensive treatment.  Collaborative care was also 
described as office based with the same treatment as primary care but included further benefits of 
treatment coordination, additional counseling, referrals, crisis management, and other services 
from a nurse case manager (Barry et al., 2016).  All treatment vignettes were also described to 
participants as having no out-of-pocket costs and being available in their area with open 
appointments (Barry et al., 2016).  
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Results of participants who were willing to enter treatment (n = 107) were 24.6% from 
the usual care group, 37.2% from the primary care group (12.6 percentage point difference; 95% 
CI = .8, 24.4), and 34.0% from the collaborative care group (9.4 percentage point difference; 
95% CI = -2.0, 20.8); willingness to enter treatment was comparable between the primary care 
and collaborative care groups (3.2 percentage point difference, 95% CI = -9.8, 16.3) (Barry et al., 
2016).  Among participants who were not willing to enter treatment (n = 237), the most common 
reason reported was the belief that treatment was not needed (63%); there was no significant 
difference among the three groups (p = .48).   
The results of this study concluded that participants with a substance use disorder were 
more willing to enter primary care-based treatment versus usual care in a specialty drug 
treatment facility (Barry et al., 2016).  Though encouraging, the results of this study were not 
generalizable to the entire population of substance use disorder as participants were limited to 
include only individuals with no prior treatment experience (Barry et al., 2016).  Previous 
experience with treatment was important to consider as it may affect the individual's beliefs 
about the effectiveness and desirability of different treatment settings (Barry et al., 2016).  
Another limitation of the study was the treatment vignette did not explicitly describe the setting 
of the specialty drug treatment center.  It was not made clear that the specialty drug treatment 
was provided in an outpatient treatment center, not a residential facility, which could have 
produced varying results (Barry et al., 2016).  Despite the limitations, the study indicates that 
broader availability of primary care-based treatment options may be useful in increasing 
treatment rates (Barry et al., 2016). 
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Nurse Practitioner Role 
 Opioid dependency should be approached as any chronic disorder, requiring continuing 
care throughout the lifespan.  Successful treatment is dependent on adherence to medications and 
behavioral changes, which are designed to increase functional status, quality of life, life 
expectancy, and to reduce factors for recurrence of the disorder.  Multiple quality and 
effectiveness of care outcome comparison studies have identified no significant differences in 
patient care outcomes between NPs and physicians in the provision of general care for chronic 
illnesses (Stanik-Hutt et al., 2013).  NP roles in health, healthcare prevention, and outcome 
improvement have been continually evolving and expanding.  The provision of naltrexone for 
opioid dependency in the family practice setting has been encompassed in that role as a result of 
the opioid epidemic and recommendations for early identification and treatment of the disease 
(AANP, 2015; ASAM, 2013).  
In searching the SAMHSA, DOJ DEA, State of Alaska, and other websites, was unclear 
of the exact number of MAT providers who were truly available in Alaska.  According to the 
Opiate Addiction and Treatment Resource website, there were 19 physicians certified to 
prescribe buprenorphine in the Anchorage/Mat-Su area; however, this information was last 
updated in January 2014 (Opiate Addiction and Treatment Resource, n.d.).  The site also listed 
one OTP in Anchorage and one in Fairbanks; again, the accuracy of this information was unclear 
as it was last updated in October of 2013 (Opiate Addiction and Treatment Resource, n.d.).  The 
limited number of MAT providers currently available compared to the most recent number of 
opioid abusers suggested the need for increased community access to MAT.  
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Methods 
Conceptual Framework 
The plan, do, study, act (PDSA) is a model that provides a framework for developing, 
testing, and implementing changes leading to quality improvement of care (Agency for 
Healthcare Research and Quality [AHRQ], 2015).  The PDSA cycle was utilized to provide the 
framework for implementation of an evidence-based toolkit that included guidelines, protocols, 
or information necessary for the provision of XR-NTX in an outpatient family practice setting.  
The goal of the PDSA cycle application was to determine if the MAT toolkit would increase 
provider knowledge of available MAT options for opioid dependence and if it would facilitate 
the adoption of MAT into clinical practice. 
The four stages of the PDSA cycle are plan, do, study, and act. In the planning stage, the 
primary investigator identifies the change to be tested or implemented and a method for data 
collection.  The second stage, the do phase, consists of carrying out the plan in step one.  The 
next stage is the study period, which is the analysis of the data and summarization of what is 
learned.  The final stage of the PDSA cycle is act.  In the act stage, implementation revisions are 
made and the planning of the next PDSA cycle occurs. 
Plan.  The initial step of the Planning stage was to identify the topic and problem for this 
quality improvement project.  After reviewing current guidelines and evaluating the literature, 
the project objectives, goals, and timeline were determined.  This step also involved developing 
an educational presentation for primary care opioid dependence treatment using XR-NTX by 
nurse practitioners, the development of a post-implementation questionnaire to assess knowledge 
of MAT therapy, and assembling supportive clinical tools that would promote practitioner 
comfort and safe use of XR-NTX.  The owner of an outpatient family practice clinic expressed 
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interest in the project topic and provided project implementation support; four of the five 
providers employed in the center voluntarily participated in this project.  
Do.  The second stage of PDSA is the Do phase, which was completed on April 8, 2017.  
This stage encompassed three parts:  
1. Delivering an educational presentation as the implementation part of this 
project (see Appendix B). 
2. Dissemination of the MAT Toolkit (see Appendix C). 
3. Survey evaluation of the presentation and MAT Toolkit (see Appendix D).  All 
participants were expected to complete the questionnaire after the presentation 
of the information.  
Study.  The third stage, or Study phase, included analyzing the post-implementation 
survey data for provider knowledge of MAT therapy after education, intent to provide MAT and 
the future use of the toolkit, and recommended areas of improvement of the clinical toolkit.  The 
collected survey results included ordinal data from the Likert scale questions, data from multiple 
choice questions, and feedback from the open-ended question.  The questionnaire results were 
evaluated and analyzed for measures of central tendency.  Provider knowledge, intent to provide 
MAT and utilization of the toolkit, and kit improvement suggestions are reported using 
descriptive statistics and frequency distributions.    
Act.  The final stage, or “Act” phase, involved performing revisions to the MAT toolkit 
as suggested by project participants before the redistribution and dissemination of the materials.  
The revised toolkit will be disseminated to the pilot clinic and will be made available on the 
Alaska Nurse Practitioner Association (ANPA) website.  A poster presentation at the 2017 
ANPA conference will be available. 
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Rights of Human Subjects 
Agreement and support from the pilot clinic administration were obtained before the 
project implementation.  The project was submitted and approved by the UAA IRB as not human 
subject research (see Appendix A).  The project did not contain human subjects and participation 
was voluntary.  Education and training were provided along with a post-implementation survey; 
the survey information was de-identified and used only to evaluate the project improvement 
goals.  
Results 
The post-implementation survey was comprised of seven questions.  Questions one 
through four were multiple choice, questions five and six were a 5-point Likert scale, and 
question 7 called for an open-ended response (see Appendix D).  The questionnaire was 
completed by all four participants.  The result of each question is listed and detailed separately in 
the following section. 
Question 1: What are the three MAT medications approved by the Food and Drug 
Administration (FDA) for the treatment of opioid dependence? 
One hundred percent (4 of 4) of the participants chose the correct answer of methadone, 
naltrexone, and buprenorphine. 
Question 2: Special certifications or prescriptive authority (aside from a DEA license) are 
required for all three MAT medications.   
One hundred percent (4 of 4) of the participants chose the correct answer of false. 
Question 3: For some opioid dependent patients, MAT is not necessary once they are past the 
detoxification phase and have been opioid-free for at least 7 to 10 days.   
One hundred percent (4 of 4) of the participants chose the correct answer of false. 
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Question 4: Treatment for opioid dependence should be approached like other chronic diseases 
such as diabetes, asthma, and hypertension.   
Seventy-five percent (3 of 4) of the participants agreed.  Twenty-five percent (1 of 4) of 
the participants neither agreed nor disagreed. 
Question 5: How likely are you to provide medication-assisted treatment for opioid dependence 
after toolkit dissemination? 
Fifty percent (2 of 4) of participants answered very likely.  Fifty percent (2 of 4) 
responded somewhat likely. 
Question 6: Do you intend to use the MAT toolkit in future practice?   
Seventy-five percent (3 of 4) of the participants answered definitely.  Twenty-five 
percent (1 of 4) participants answered most likely.   
Question 7: Is there any information you feel would be helpful to include in the toolkit?   
 A true pocket-sized "MAT of Opioid Use Disorder, Pocket Guide."  
 A list of support group contacts, mental health counselors, and substance abuse 
counselors 
 You included all of the major factors that I would need to be comfortable, except need 
more instructions on treatment of opioid withdrawal before MAT initiation 
 A template for electronic medical record 
Discussion and Conclusion 
Implementation Barriers 
The first obstacle encountered was the delay of University of Alaska Anchorage (UAA) 
Institutional Review Board (IRB) request for determination of human subject research.  The 
initial application submission on January 16, 2017 resulted in a response received February 10, 
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2017 and determined the project to be human subject research.  The revision of evaluation 
methods was required to focus on participant knowledge and recommendations for toolkit 
improvement versus the actual participants and their perceptions.  Submission of a revised IRB 
application took place March 06, 2017 and immediate approval by the IRB compliance officer 
was received the same day indicating the project was not human subject research.  
The next obstacle encountered was the gathering of all components necessary for the 
MAT toolkit.  Permission to utilize copyrighted materials and ordering the materials took more 
time than anticipated.  Time constraints also affected the ability to evaluate participant utilization 
of the MAT toolkit.  The MAT modality education, toolkit dissemination, and post-
implementation survey occurred on the same day due to the limited time available for project 
completion.  Because of this time constraint, participant intent to provide MAT for opioid 
dependency and intent to use the toolkit in future clinical practice is based on the satisfaction of 
the information presented and not the clinical practicality; participants did not have the 
opportunity to utilize the materials in practice over four to six weeks as originally planned. 
Project Limitations 
Several limitations were identified during and after the completion of this quality 
improvement project.  The sample size was small as only one outpatient primary clinic was used.  
The small non-probability convenience sampling limits the generalizability of the project 
findings.  Time constraints prevented the use of the toolkit by participants over four to six weeks 
as originally planned, which could have provided data on actual provider implementation of the 
toolkit and not just intent to use.  Also, a pre-education survey may have provided more accurate 
measures of provider knowledge before and after the MAT education presentation.   
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Outcomes 
The two intended goals of this project were (1) to increase knowledge of MAT options 
for opioid dependence, and (2) to develop a MAT toolkit to facilitate utilization of MAT into 
clinical practice; both goals were partially met.  The first four questions of the post-
implementation survey measured knowledge; three questions were answered correctly by 100% 
of the participants, and one question was answered correctly by 75% of the participants.  
Questions five and six assessed provider intent to provide MAT after the toolkit dissemination 
and intent to use the toolkit in future clinical practice.  All participants were somewhat likely or 
very likely to provide MAT and all participants most likely or definitely intended to use the 
toolkit in future practice.  While the MAT toolkit assembled contained information providers felt 
necessary to facilitate MAT into clinical practice, there was no data measuring that they did 
indeed utilize the toolkit or implement MAT.  
Overall, the education of MAT modalities and the toolkit for opioid dependence were 
well received by all participants.  The intent to provide MAT for opioid dependency, their intent 
to utilize the MAT toolkit in future clinical practice; and 100% participant response and feedback 
from the open-ended question is encouraging for further studies.  Further studies could provide 
data on actual toolkit use by providers and the comparison of MAT patients before and after 
toolkit implementation to assess increased access and availability.  Future projects with a larger 
sample size could also identify other beneficial components to include in the toolkit and keep 
providers abreast of the most current evidence-based guidelines.   
Significance for Advanced Nursing Practice 
The development of an outpatient primary care evidence-based toolkit for MAT in opioid 
dependence for Alaska NPs can enhance awareness and knowledge of current MAT options.  It 
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can also assist in the provision of safe, effective, evidence-based care, facilitate the 
implementation of MAT into clinical practice, and increase the number of NPs who can provide 
MAT.  Increasing the number of providers who are knowledgeable and able to provide MAT for 
opioid dependent people can increase the access and availability of MAT, which could decrease 
the significant widespread impacts of this disease (NIDA, 2012; Volkow et al., 2014).  
Increasing the access and availability could offer positive outcomes to opioid dependent persons, 
their families, and the community.  
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Appendix A 
IRB Determination 
 
From: Sharilyn Mumaw simumaw@alaska.edu
Subject: Re: Request for IRB determination form
Date: March 6, 2017 at 1:15 PM
To: Charlene Hill chill64@alaska.edu
Cc: Sharilyn I Mumaw simumaw@uaa.alaska.edu, Lisa Jackson lmjackson2@alaska.edu
Charlene,
Here is your copy of your determination of not HSR.
Regards,
Sharilyn
On Mon, Mar 6, 2017 at 7:01 AM, Charlene Hill <chill64@alaska.edu> wrote:
Good morning Sharilyn,
Please ﬁnd attached is a revised/updated IRB determination form for my project.
~Charlene Hill
> On Jan 16, 2017, at 3:18 PM, Charlene Hill <chill64@alaska.edu> wrote:
>
> <Hill_Request for IRB Determination.pdf>
-- 
Sharilyn Mumaw, M.P.A.
Research Integrity and Compliance Officer
Research and Graduate Studies | University of Alaska Anchorage
3211 Providence Drive | BOC-3 376 | Anchorage, Alaska 99508
simumaw@uaa.alaska.edu | 907-786-1099
SoN - Hill - ND 696
Opiod Depe…t HSR.pdf
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Appendix B 
Project Implementation  
You are invited to participate in the use of a medication-assisted treatment (MAT) toolkit for the 
treatment of opioid dependency.  The toolkit is part of a practice improvement project for MAT 
in opioid dependency being conducted by Charlene Hill, BSN, RN as part of the requirements 
for a Master of Science in Nursing Science degree with the University of Alaska Anchorage.   
 
Use of the MAT toolkit is voluntary; you will be asked to complete a brief follow-up survey 
regarding the toolkit.  There are no risks associated with participation as the survey collects no 
identifying data of any respondent and all responses will be recorded anonymously.  If you have 
any questions regarding participation in the survey or the practice improvement project, please 
contact Charlene Hill, BSN, RN at chill64@alaska.edu. 
 
Your participation is voluntary and is greatly appreciated.  
 
Current practice recommendations indicate that opioid dependency is a chronic illness 
and should be treated with a combination of psychosocial and pharmacotherapy (American 
Society of Addiction Medicine [ASAM], 2015; National Guideline Clearinghouse [NGC], 2011).  
There are three MAT medications approved by the Food and Drug Administration (FDA) for the 
treatment of opioid dependence. 
1. Methadone 
2. Buprenorphine 
3. Naltrexone 
Methadone and Buprenorphine require special certifications and special prescriptive 
authority, whereas any healthcare provider who can write prescriptions can prescribe naltrexone.  
Nurse practitioners who are willing to provide MAT with naltrexone can help increase patient 
access to treatment and positively impact the opioid epidemic. 
Practice guidelines recommend treatment of opioid use disorders to include a 
combination of withdrawal management and psychosocial therapy or psychosocial therapy 
combined with methadone, buprenorphine, or naltrexone (ASAM, 2015).  Aside from methadone 
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and buprenorphine, the alpha2-adrenergic agonist clonidine has also been used an effective 
treatment for opioid withdrawal management (Gowing, Farrell, Ali, & White, 2016).  While a 
recent systematic review of the literature found that clonidine was more effective than placebo in 
the management of opioid withdrawal, clonidine is not an FDA approved medication for this 
indication (Gowing et al., 2016; ASAM, 2015).  As such, withdrawal management will not be 
discussed in depth, as Nurse Practitioner prescriptive authority for MAT is limited to naltrexone.  
Caution should be taken to prevent severe withdrawal symptoms caused by naltrexone, and 
should only be used after detoxification and when the individual is no longer physically 
dependent on opioids (ASAM, 2015; SAMHSA, 2016a).  It is also important to note that 
detoxification alone is not a recommended treatment for opioid dependency (ASAM, 2015).  
The once-monthly injectable Naltrexone (Vivitrol) has been approved for both opioid and 
alcohol dependence; however, this project is specific to opioid dependency and therefore will not 
include alcohol treatment information.  Upon request, the Alkermes Vivitrol pharmaceutical 
representative may provide further information regarding treatment of alcohol dependence and 
opioid detoxification protocols.  
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Appendix C 
MAT Toolkit 
The following information, referred to as the MAT toolkit, has been gathered and 
provided to facilitate MAT in your clinical practice.   
The MAT toolkit includes:  
 MAT of Opioid Use Disorder, Pocket Guide – a resource provided by Substance Abuse 
and Mental Health Services Administration (SAMHSA) with information on the three 
available MAT medications  
 Medical Provider Checklist – screening tool to help decide if Vivitrol is appropriate for 
your patient  
o Patient must be free of all opioids for at least 7 days prior to Vivitrol 
administration 
 Clinical Opiate Withdrawal Scale – tool to assess withdrawal symptoms, the need for 
inpatient detoxification, and to measure patient progress 
 Patient Education Overview – patient information handout on Vivitrol 
 Patient Counseling Tool – information to review with patients on Vivitrol at each 
encounter  
 Medication Guide to Vivitrol 
 Prescribing Information for Vivitrol 
 Patient Injection Poster – Vivitrol injection visual aid 
 Vivitrol Billing and Coverage Information and Resources – CPT and ICD-10 codes 
included 
o Providers may choose to purchase Vivitrol and bill patients insurance, send 
prescription to specialty pharmacy with delivery to the office or administration at 
the specialty pharmacy or send prescription to retail pharmacy for patient pick up 
with administration in office 
o TouchPoints Support Services – can assist providers and patients with 
prescriptions to specialty pharmacies and medication delivery, prior authorization 
support, co-pay assistance (self-pay or commercial insurance patients only), 
reimbursement coverage verification, and claims review 
o Providers may request a limited number of Vivitrol samples for immediate access 
in the clinic   
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Appendix D 
Post-Implementation Survey  
Thank you for participating in this practice improvement project for medication‐assisted treatment (MAT) for 
opioid dependency.  This final survey is intended to measure awareness and knowledge of MAT in opioid 
dependence and the overall satisfaction of the information provided to you. 
 
There are no risks associated with participation as the survey collects no identifying data of any respondent and all 
responses will be recorded anonymously.  By completing and submitting this survey, you are indicating your 
consent to participate in this practice improvement project.  Your participation and feedback is invaluable and 
greatly appreciated.   
 
1. What are the three MAT medications approved by the Food and Drug Administration (FDA) for the 
treatment of opioid dependence? 
Choose one: 
a. Methadone, naloxone, and buprenorphine 
b. Methadone, naltrexone, and buprenorphine 
c. Methadone, naltrexone, and butorphanol 
d. Methadone, nalbuphine, and buprenorphine 
e. Methadone, naltrexone, and bumetanide 
 
2. Special certifications and prescriptive authority (aside from a DEA license) are required for all three 
MAT medications.  Choose one: 
a. True 
b. False 
c. Unsure 
 
3. For some opioid dependent patients, MAT is not necessary once they are past the detoxification 
phase and have been opioid‐free for at least 7 to 10 days.  Choose one: 
a. True 
b. False 
c. Unsure 
 
4. Treatment for opioid dependence should be approached like other chronic diseases such as 
diabetes, asthma, and hypertension.   Choose one: 
a. Agree 
b. Neither agree or disagree 
c. Disagree 
 
5. How likely are you to provide medication‐assisted treatment for opioid dependence after toolkit 
dissemination?  Check one: 
_____ Very likely 
_____ Somewhat likely 
_____ Undecided 
_____ Somewhat unlikely 
_____ Very unlikely 
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6. Do you intend to use the MAT toolkit in future practice?  Check one: 
_____ Definitely 
_____ Most likely 
_____ Maybe 
_____ Not likely 
_____ Definitely not 
 
7. Is there any information you feel would be helpful to include in the toolkit? 
 
